BIOCYTOGEN-B Shares Surge Over 6% on Strong 2025 Forecast and Licensing Deals

Stock News02-11

BIOCYTOGEN-B (02315) rose more than 6% in afternoon trading. As of the time of writing, the stock was up 6.33%, reaching HK$52.95, with a turnover of HK$34.0299 million.

The increase follows the company's recent release of its 2025 performance forecast. BIOCYTOGEN-B anticipates full-year revenue to be between approximately RMB 1.369 billion and RMB 1.389 billion, representing a year-on-year increase of 39.61% to 41.65%. It also forecasts net profit attributable to shareholders to be in the range of RMB 162 million to RMB 182 million, a significant surge of 384.26% to 443.88% compared to the previous year.

Analysis suggests the strong performance is driven by BIOCYTOGEN-B's innovative advantages in model animal and preclinical CRO services, supported by its antibody platform under the "Thousand Mice Ten Thousand Antibodies" initiative. It was noted that since the beginning of 2025, the company has entered into out-licensing agreements with several leading domestic and international pharmaceutical firms. Furthermore, multiple drug pipelines have received IND approvals. As these licensed pipelines advance, the company is expected to generate additional revenue from milestone payments, potentially unlocking further long-term growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169404904?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 14:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169404904","market":"fut","top_or_hot":-1,"title":"BIOCYTOGEN-B Shares Surge Over 6% on Strong 2025 Forecast and Licensing Deals","media":"Stock News","content":"<p>BIOCYTOGEN-B (02315) rose more than 6% in afternoon trading. As of the time of writing, the stock was up 6.33%, reaching HK$52.95, with a turnover of HK$34.0299 million.</p>\n<p>The increase follows the company's recent release of its 2025 performance forecast. BIOCYTOGEN-B anticipates full-year revenue to be between approximately RMB 1.369 billion and RMB 1.389 billion, representing a year-on-year increase of 39.61% to 41.65%. It also forecasts net profit attributable to shareholders to be in the range of RMB 162 million to RMB 182 million, a significant surge of 384.26% to 443.88% compared to the previous year.</p>\n<p>Analysis suggests the strong performance is driven by BIOCYTOGEN-B's innovative advantages in model animal and preclinical CRO services, supported by its antibody platform under the \"Thousand Mice Ten Thousand Antibodies\" initiative. It was noted that since the beginning of 2025, the company has entered into out-licensing agreements with several leading domestic and international pharmaceutical firms. Furthermore, multiple drug pipelines have received IND approvals. As these licensed pipelines advance, the company is expected to generate additional revenue from milestone payments, potentially unlocking further long-term growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOCYTOGEN-B Shares Surge Over 6% on Strong 2025 Forecast and Licensing Deals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOCYTOGEN-B Shares Surge Over 6% on Strong 2025 Forecast and Licensing Deals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-11 14:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) rose more than 6% in afternoon trading. As of the time of writing, the stock was up 6.33%, reaching HK$52.95, with a turnover of HK$34.0299 million.</p>\n<p>The increase follows the company's recent release of its 2025 performance forecast. BIOCYTOGEN-B anticipates full-year revenue to be between approximately RMB 1.369 billion and RMB 1.389 billion, representing a year-on-year increase of 39.61% to 41.65%. It also forecasts net profit attributable to shareholders to be in the range of RMB 162 million to RMB 182 million, a significant surge of 384.26% to 443.88% compared to the previous year.</p>\n<p>Analysis suggests the strong performance is driven by BIOCYTOGEN-B's innovative advantages in model animal and preclinical CRO services, supported by its antibody platform under the \"Thousand Mice Ten Thousand Antibodies\" initiative. It was noted that since the beginning of 2025, the company has entered into out-licensing agreements with several leading domestic and international pharmaceutical firms. Furthermore, multiple drug pipelines have received IND approvals. As these licensed pipelines advance, the company is expected to generate additional revenue from milestone payments, potentially unlocking further long-term growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"","article_id":"1169404904","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169404904","pubTimestamp":1770789870,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOCYTOGEN-B (02315) rose more than 6% in afternoon trading. As of the time of writing, the stock was up 6.33%, reaching HK$52.95, with a turnover of HK$34.0299 million. The increase follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK0216":"研究试验","VT":"世界全股市ETF-Vanguard","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard","02315":"百奥赛图-B"},"translate_title":"由于2025年的强劲预测和许可交易，百奥赛图-B股价飙升超过6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"02315":1,"VT":1,"VXUS":1},"content_text":"BIOCYTOGEN-B (02315) rose more than 6% in afternoon trading. As of the time of writing, the stock was up 6.33%, reaching HK$52.95, with a turnover of HK$34.0299 million.\nThe increase follows the company's recent release of its 2025 performance forecast. BIOCYTOGEN-B anticipates full-year revenue to be between approximately RMB 1.369 billion and RMB 1.389 billion, representing a year-on-year increase of 39.61% to 41.65%. It also forecasts net profit attributable to shareholders to be in the range of RMB 162 million to RMB 182 million, a significant surge of 384.26% to 443.88% compared to the previous year.\nAnalysis suggests the strong performance is driven by BIOCYTOGEN-B's innovative advantages in model animal and preclinical CRO services, supported by its antibody platform under the \"Thousand Mice Ten Thousand Antibodies\" initiative. It was noted that since the beginning of 2025, the company has entered into out-licensing agreements with several leading domestic and international pharmaceutical firms. Furthermore, multiple drug pipelines have received IND approvals. As these licensed pipelines advance, the company is expected to generate additional revenue from milestone payments, potentially unlocking further long-term growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169404904","isCrawlerRequest":true}